FAMILIAL HYPERCHOLESTROLEMIA
PYARI JAAN BASHEER AHMED
GROUP 8
TBILISI STATE MEDICAL UNIVERSITY
INTRODUCTION
 Familial hypercholesterolemia (FH) have raised cholesterol levels in blood
with a significant risk of developing early CAD.
 FH is an autosomal dominant disorder occurs in 1 in 500 individuals.
 Usually due to mutations in LDL receptor gene that result in decreased
clearance of LDL particles from plasma
 Other mutations include those in the Apo B ,ARH and PCSK9 genes
CLINICAL MANIFESTATIONS
• High cholesterol level in blood.
• Heterozygotes may have premature cardiovascular
disease at the age of 30 to 40.
• homozygous may cause severe cardiovascular disease in
childhood.
• Accompanied by cholesterol deposition in tendons and skin
(xanthomas) and in the eyes
A- Xanthelasma
B – Corneal arcus
(Arcus senilis)
C - Achilles tendon
xanthomas
D - Tendon xanthomas
E - Tuberous xanthomas
F - Palmar xanthomas
PLASMA CHOLESTEROL LEVEL IN
NORMAL AND FH INDIVIDUALS
 NORMAL – 150 – 200 mg/dl
 FH HETEROZYTOGE – 200 – 500 mg/dl
 FH HOMOZYGOTES – 600 – 1000 mg/ dl
FH Is Not a Rare Genetic Disease:
Prevalence is 2x Other Inherited Conditions
1. Genetic Alliance UK. Available at http://www.geneticalliance.org.uk/education3.htm.
2. Streetly A, et al. J Clin Path. 2010;63:626-629.
Neuro-
fibromatosis
Frequency per 1,000 Births of
Common Genetic Disorders1
2FH
2.0
Function of LDLR gene
 The LDLR gene is located on 19p13.2
 The LDLR gene provides instructions for making a protein called low
density lipoprotein receptor
 This receptor binds to particles called low-density lipoproteins, which are
the primary carriers of cholesterol in the blood.
 They are particularly abundant in the liver, which is the organ
responsible for removing most excess cholesterol from the body.
Mutation in LDLR gene
 Mutations in the LDLR gene cause FH
 More than 1,000 mutations have been identified in this gene.
 Some genetic changes reduce the no. of low-density lipoprotein receptor and
other mutations disrupt the receptor's ability to remove low-density
lipoproteins from the blood.
 As a result, people with mutations in the LDLR gene have very high blood
cholesterol levels.
 The excess cholesterol circulates through the bloodstream, is deposited
abnormally in tissues such as the skin, tendons.
 And also arteries that supply blood to the heart (coronary arteries) results in
heart attack.
CLASSES OF MUTATION IN LDLR
 Class 1 mutations affect the synthesis of the receptor in the
endoplasmic reticulum (ER).
 Class 2 mutations prevent proper transport to the Golgi
body needed for modifications to the receptor
 Class 3 mutations stop the binding of LDL to the receptor..
 Class 4 mutations inhibit the internalisation of the receptor-ligand
complex
 Class 5 mutations give rise to receptors that cannot recycle
properly. This leads to a relatively mild phenotype as receptors are
still present on the cell surface
 Class 6 Failure to localize receptor to the basolateral domain
Function of APOE gene
 The APOB gene is located on 2p24-p23
 The APOB gene provides instructions for making two versions of the apolipoprotein B
protein, a short version called apolipoprotein B-48 and a longer version known as
apolipoprotein B-100.
 Both of these proteins are components of lipoproteins.
 Apolipoprotein B-48 is produced in the intestine, where it is a building block of a type of
lipoprotein called a chylomicron.
 Apolipoprotein B-100, which is produced in the liver, is a component of several other
types of lipoproteins
Mutation in APOE gene
 At least five mutations in the APOB gene are known to cause a form of inherited
hypercholesterolemia.
 Each mutation that causes this condition changes a single amino acid in a critical region
of apolipoprotein B-100.
 The altered protein prevents low-density lipoproteins from effectively binding to their
receptors on the surface of cells.
 As a result, fewer low-density lipoproteins are removed from the blood, and cholesterol
levels are much higher than normal.
Function of LDLRAP1 Gene
 The LDLRAP1 gene is located on 1p36-p35.
 The LDLRAP1 gene is also known as ARH( Autosomal recessive hypercholesterolemia)
 The LDLRAP1 gene provides instructions for making a protein LDLRAP1 that helps
remove cholesterol from the bloodstream.
 The LDLRAP1 protein interacts with a protein called a low-density lipoprotein receptor.
 The LDLRAP1 protein appears to play a critical role in moving these receptors, together
with their attached low-density lipoproteins, from the cell surface to the interior of the
cell.
Mutation in LDLRAP1 gene
 More than 10 mutations in the LDLRAP1 gene have been shown to cause a form of
inherited high cholesterol called ARH
 These mutations lead to the production of an abnormally small, nonfunctional version of
the LDLRAP1 protein or prevent cells from making any of this protein.
 Without the LDLRAP1 protein, LDL receptors are unable to remove LDL’s from the
bloodstream effective.
 The receptors can still bind normally to low-density lipoproteins, but not properly
transported into cells . As a result,more low-density lipoproteins remain in the blood.
FUNCTION OF PCSK9 GENE
 The PCSK9 protein appears to control the number of low-density
lipoprotein receptors, which are proteins on the surface of cell
 the PCSK9 protein helps control blood cholesterol levels by breaking
down low-density lipoprotein receptors before they reach the cell
surface.
Mutation
GAIN OF FUNCTION: The mutations responsible for hypercholesterolemia as "gain-of-function"
because they appear to enhance the activity of the PCSK9 protein or give the protein a new,
atypical function.
Altered protein may cause these receptors to be broken down more quickly than
usual. With fewer receptors to remove low
LOSS OF FUNCTION: Loss-of-function mutations in the PCSK9 gene appear to be more common than
gain-of-function mutations, which are responsible for hypercholesterolemia.
Loss-of-function mutations in the PCSK9 gene lead to an increase in the number of
low-density lipoprotein receptors on the surface of liver cells.
The 4 Genes Associated with FH
Mutant
Gene
Product
Pattern of
Inheritance
Prevalence Effect of
Disease-
Causing
Mutations
Typical LDL
Cholesterol
Level (Normal
Adults:
~120 mg/dL)
LDL
receptor
AD
(19p13.2)
HTZs: 1/500
HMZs:
1/106
Loss of
function
HTZs: 350
HMZs: 700
Apo B-100 AD
(2p24)
HTZs:
1/1000*
HMZs:
1/106*
Loss of
function
HTZs: 270
HMZs: 320
ARH
adaptor Pr.
AR
(1p36-p35)
Very rare† Loss of
function
HMZs: 470
PCSK9
protease
AD
(1p34.1-p32 )
Very rare Gain of
function
HTZs: 225
TREATMENT
 Heterozygous FH is normally treated with statins-drugs that lower
cholesterol level
 Bile acid sequestrants (hypolipidemic agents), Ezetimibe,
Fibrates (such as gemfibrozil or fenofibrate) and nicotinic acid
 Also other hypolipidemic agents that lower cholesterol levels.
 Homozygous FH often does not respond to regular medical
therapy and may require LDL-apheresis (removal of LDL in a
method similar to dialysis) and occasionally liver transplantation.
 Dietary reduction of cholesterol, and healthy lifestyle
Familial hypercholestrolemia

Familial hypercholestrolemia

  • 1.
    FAMILIAL HYPERCHOLESTROLEMIA PYARI JAANBASHEER AHMED GROUP 8 TBILISI STATE MEDICAL UNIVERSITY
  • 2.
    INTRODUCTION  Familial hypercholesterolemia(FH) have raised cholesterol levels in blood with a significant risk of developing early CAD.  FH is an autosomal dominant disorder occurs in 1 in 500 individuals.  Usually due to mutations in LDL receptor gene that result in decreased clearance of LDL particles from plasma  Other mutations include those in the Apo B ,ARH and PCSK9 genes
  • 3.
    CLINICAL MANIFESTATIONS • Highcholesterol level in blood. • Heterozygotes may have premature cardiovascular disease at the age of 30 to 40. • homozygous may cause severe cardiovascular disease in childhood. • Accompanied by cholesterol deposition in tendons and skin (xanthomas) and in the eyes
  • 4.
    A- Xanthelasma B –Corneal arcus (Arcus senilis) C - Achilles tendon xanthomas D - Tendon xanthomas E - Tuberous xanthomas F - Palmar xanthomas
  • 5.
    PLASMA CHOLESTEROL LEVELIN NORMAL AND FH INDIVIDUALS  NORMAL – 150 – 200 mg/dl  FH HETEROZYTOGE – 200 – 500 mg/dl  FH HOMOZYGOTES – 600 – 1000 mg/ dl
  • 6.
    FH Is Nota Rare Genetic Disease: Prevalence is 2x Other Inherited Conditions 1. Genetic Alliance UK. Available at http://www.geneticalliance.org.uk/education3.htm. 2. Streetly A, et al. J Clin Path. 2010;63:626-629. Neuro- fibromatosis Frequency per 1,000 Births of Common Genetic Disorders1 2FH 2.0
  • 7.
    Function of LDLRgene  The LDLR gene is located on 19p13.2  The LDLR gene provides instructions for making a protein called low density lipoprotein receptor  This receptor binds to particles called low-density lipoproteins, which are the primary carriers of cholesterol in the blood.  They are particularly abundant in the liver, which is the organ responsible for removing most excess cholesterol from the body.
  • 8.
    Mutation in LDLRgene  Mutations in the LDLR gene cause FH  More than 1,000 mutations have been identified in this gene.  Some genetic changes reduce the no. of low-density lipoprotein receptor and other mutations disrupt the receptor's ability to remove low-density lipoproteins from the blood.  As a result, people with mutations in the LDLR gene have very high blood cholesterol levels.  The excess cholesterol circulates through the bloodstream, is deposited abnormally in tissues such as the skin, tendons.  And also arteries that supply blood to the heart (coronary arteries) results in heart attack.
  • 11.
    CLASSES OF MUTATIONIN LDLR  Class 1 mutations affect the synthesis of the receptor in the endoplasmic reticulum (ER).  Class 2 mutations prevent proper transport to the Golgi body needed for modifications to the receptor  Class 3 mutations stop the binding of LDL to the receptor..  Class 4 mutations inhibit the internalisation of the receptor-ligand complex  Class 5 mutations give rise to receptors that cannot recycle properly. This leads to a relatively mild phenotype as receptors are still present on the cell surface  Class 6 Failure to localize receptor to the basolateral domain
  • 13.
    Function of APOEgene  The APOB gene is located on 2p24-p23  The APOB gene provides instructions for making two versions of the apolipoprotein B protein, a short version called apolipoprotein B-48 and a longer version known as apolipoprotein B-100.  Both of these proteins are components of lipoproteins.  Apolipoprotein B-48 is produced in the intestine, where it is a building block of a type of lipoprotein called a chylomicron.  Apolipoprotein B-100, which is produced in the liver, is a component of several other types of lipoproteins
  • 14.
    Mutation in APOEgene  At least five mutations in the APOB gene are known to cause a form of inherited hypercholesterolemia.  Each mutation that causes this condition changes a single amino acid in a critical region of apolipoprotein B-100.  The altered protein prevents low-density lipoproteins from effectively binding to their receptors on the surface of cells.  As a result, fewer low-density lipoproteins are removed from the blood, and cholesterol levels are much higher than normal.
  • 15.
    Function of LDLRAP1Gene  The LDLRAP1 gene is located on 1p36-p35.  The LDLRAP1 gene is also known as ARH( Autosomal recessive hypercholesterolemia)  The LDLRAP1 gene provides instructions for making a protein LDLRAP1 that helps remove cholesterol from the bloodstream.  The LDLRAP1 protein interacts with a protein called a low-density lipoprotein receptor.  The LDLRAP1 protein appears to play a critical role in moving these receptors, together with their attached low-density lipoproteins, from the cell surface to the interior of the cell.
  • 16.
    Mutation in LDLRAP1gene  More than 10 mutations in the LDLRAP1 gene have been shown to cause a form of inherited high cholesterol called ARH  These mutations lead to the production of an abnormally small, nonfunctional version of the LDLRAP1 protein or prevent cells from making any of this protein.  Without the LDLRAP1 protein, LDL receptors are unable to remove LDL’s from the bloodstream effective.  The receptors can still bind normally to low-density lipoproteins, but not properly transported into cells . As a result,more low-density lipoproteins remain in the blood.
  • 17.
    FUNCTION OF PCSK9GENE  The PCSK9 protein appears to control the number of low-density lipoprotein receptors, which are proteins on the surface of cell  the PCSK9 protein helps control blood cholesterol levels by breaking down low-density lipoprotein receptors before they reach the cell surface.
  • 18.
    Mutation GAIN OF FUNCTION:The mutations responsible for hypercholesterolemia as "gain-of-function" because they appear to enhance the activity of the PCSK9 protein or give the protein a new, atypical function. Altered protein may cause these receptors to be broken down more quickly than usual. With fewer receptors to remove low LOSS OF FUNCTION: Loss-of-function mutations in the PCSK9 gene appear to be more common than gain-of-function mutations, which are responsible for hypercholesterolemia. Loss-of-function mutations in the PCSK9 gene lead to an increase in the number of low-density lipoprotein receptors on the surface of liver cells.
  • 19.
    The 4 GenesAssociated with FH Mutant Gene Product Pattern of Inheritance Prevalence Effect of Disease- Causing Mutations Typical LDL Cholesterol Level (Normal Adults: ~120 mg/dL) LDL receptor AD (19p13.2) HTZs: 1/500 HMZs: 1/106 Loss of function HTZs: 350 HMZs: 700 Apo B-100 AD (2p24) HTZs: 1/1000* HMZs: 1/106* Loss of function HTZs: 270 HMZs: 320 ARH adaptor Pr. AR (1p36-p35) Very rare† Loss of function HMZs: 470 PCSK9 protease AD (1p34.1-p32 ) Very rare Gain of function HTZs: 225
  • 20.
    TREATMENT  Heterozygous FHis normally treated with statins-drugs that lower cholesterol level  Bile acid sequestrants (hypolipidemic agents), Ezetimibe, Fibrates (such as gemfibrozil or fenofibrate) and nicotinic acid  Also other hypolipidemic agents that lower cholesterol levels.  Homozygous FH often does not respond to regular medical therapy and may require LDL-apheresis (removal of LDL in a method similar to dialysis) and occasionally liver transplantation.  Dietary reduction of cholesterol, and healthy lifestyle

Editor's Notes

  • #7 Mutations in Apo B and PCSK9 are less common that those in LDLR (1:2,500 and 1:1,000, respectively).2